A PHASE IB DOSE-ESCALATION TRIAL OF ISATUXIMAB (SAR650984, ANTI-CD38 MAB) PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM RESULTS FROM 2 NEW DOSE COHORTS
HAEMATOLOGICA(2016)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要